- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02239432
Telomere Biology in Early Adenocarcinoma of the Lung
Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung
Early adenocarcinoma of the lung has an excellent five-year survival after resection. However, its clinical and radiologic presentation is highly variable. Traditional means for preoperative diagnosis such as Positron Emission Tomography (PET-CT) and trans-thoracic needle biopsy demonstrate unacceptable false positive and negative rates.
Telomere biology is activated aberrantly is most lung cancers but has not been studied in early stages to the best of our knowledge.
The objective of this study is to evaluate telomere length and activity with suspected early stage adenocarcinoma of the lung.
Study Overview
Status
Detailed Description
Bronchoalveolar carcinoma has been traditionally used to refer to a subset of adenocarcinoma distinguished by its peripheral location, typical "lepidic" growth pattern and tendency for both bronchogenic and lymphatic spread. For the purpose of this discussion and consistency with the revised 2011 criteria, BAC subtypes will be collectively referred to as early adenocarcinoma.
The clinical presentation of early adenocarcinoma subtypes is highly variable ranging from a small solitary nodule to extensive lobar consolidation. Many peripheral lesions have a characteristic ground glass opacity appearance on Chest CT, which may correlate with an improved prognosis. The reported five-year disease-free survival after resection for isolated lesions may approaches 100%.
Preoperative diagnosis of such lesions is complicated by several limitations. First, the differential diagnosis is broad including an extensive number of inflammatory and infectious processes. Second, positron emission tomography (PET), which identifies regions of increased metabolic activity, may be falsely negative due to the slow growth of early adenocarcinoma lesions. Transbronchial needle biopsy is also unreliable to confirm or exclude disease in non-solid type lesions.
The proportion of lung cancers classified as adenocarcinoma has steadily increased and now comprises nearly ½ of cases. However, the proportion of adenocarcinoma in situ is uncertain. Previous reports range from 5-10% in a large series to as high as 24% in the large Surveillance, Epidemiology and End Results database. Thus, these early adenocarcinoma lesions may represent a disproportionately large number of lung cancers which are PET negative yet carry an excellent prognosis after early resection. The early adenocarcinoma subtypes represent a clinical entity requiring further characterization to distinguish lesions more likely to be malignant from benign.
Telomerase is activated aberrantly in most lung cancers and mutations in telomerase components predispose to solid malignancies. For patients with non-small cell lung cancer, numerous studies correlate increased tumor telomerase activity with increased likelihood of Stage IIIB and Stage IV disease and/or reduced survival. Furthermore, telomerase inhibition is currently being studied in clinical trials of patients with advanced non-small lung cancer.
Problem:
The semi-solid lung lesion may represent early stage adenocarcinoma which has an excellent prognosis upon early diagnosis and prompt surgical resection. However, the semi-solid lesion has a broad differential diagnosis and preoperative features characteristic of adenocarcinoma are needed to distinguish malignant from benign lesions.
Objective:
To study telomere length and telomerase activity in patients with suspected early adenocarcinoma of the lung whom are referred for surgical biopsy of lung lesions.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Matthew Koslow, M.D.
- Phone Number: +972-3-52-603-5410
- Email: mkoslow73@gmail.com
Study Contact Backup
- Name: David Shitrit, M.D.
- Phone Number: +972-9-747-1556
- Email: Davids3@clalit.org.il
Study Locations
-
-
-
Beer Sheva, Israel, 84101
- Recruiting
- Soroka University Medical Center
-
Contact:
- Yael Rafaely, M.D.
- Email: YaelRefaely@clalit.org.il
-
Contact:
- Alina Zilberman, Msc
- Email: ElinuRu@clalit.org.il
-
Principal Investigator:
- Yael Rafaely, M.D.
-
Kfar Saba, Israel, 4428164
- Recruiting
- Meir Medical Center
-
Contact:
- Matthew Koslow, M.D.
- Phone Number: +972-52-603-5410
- Email: mkoslow73@gmail.com
-
Principal Investigator:
- Matthew Koslow, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients referred by a multi-disciplinary team meeting recommendation for surgical lung biopsy due to suspected adenocarcinoma of the lung and agree to a one-time peripheral blood sample for telomere analysis as described.
Exclusion Criteria:
Patients whom were not evaluated by the multi-disciplinary team discussion prior to referral for surgical lung biopsy.
Patients with other chronic inflammatory disease requiring immunosuppressive therapy or known extra-pulmonary malignancy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Suspected Adenocarcinoma of the Lung
Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
|
Healthy Control
Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
|
Age-matched controls with proven solid lung malignancy
Patients with biopsy-proven advanced solid malignancy of the lung
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Telomere Capture Percentage
Time Frame: one-time peripheral blood sample
|
According to our previous experience with telomore biology in different disease states, we estimate a standard deviation (SD) of 1.3 of telomere capture (%) for the controls (healthy patients without known lung disease) and a SD of 2.4 (TC%) for biopsy-proven adenocarcinoma of the lung.
For a clinically significance of at least 2%, we estimate a sample size of at least 16 patients with biopsy-proven disease to detect a statistically significant of 5% with a power of 80% (calculated by the independent t-test).
|
one-time peripheral blood sample
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0067-14-MMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma, Bronchiolo-Alveolar
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedAdenocarcinoma, Bronchiolo-AlveolarFrance
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Millennium Pharmaceuticals, Inc.TerminatedCarcinoma, Non-Small-Cell Lung | Adenocarcinoma, Bronchiolo-AlveolarUnited States
-
AZ-VUBHoffmann-La RocheUnknownLung Neoplasms | Non-Small Cell Lung Cancer | Adenocarcinoma, Bronchiolo-AlveolarBelgium
-
National Cancer Institute (NCI)Active, not recruitingLung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenosquamous CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed SubtypeUnited States
-
National Cancer Institute (NCI)TerminatedLung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Large Cell Lung Carcinoma | Bronchioloalveolar Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedLung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedSquamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung CancerUnited States